Diffusion Pharmaceuticals (DFFN) Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Diffusion Pharmaceuticals (DFFNResearch Report) today. The company’s shares closed last Thursday at $0.53, close to its 52-week low of $0.51.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 25.9% and a 46.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Corvus Pharmaceuticals, and Cellectar Biosciences.

The word on The Street in general, suggests a Hold analyst consensus rating for Diffusion Pharmaceuticals.

See today’s analyst top recommended stocks >>

Diffusion Pharmaceuticals’ market cap is currently $53.57M and has a P/E ratio of -1.90. The company has a Price to Book ratio of 1.22.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Read More on DFFN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed